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Twenty years ago, R. Steinman and colleagues established
that dendritic cells (DCs) have unique capacities to prime
naive T cells and that DC maturation is the checkpoint for
the initiation of adaptive immune responses (1–3). In the
mid-1990s, C. Janeway pointed out the pivotal role of in-
nate effectors in dictating adaptive immune responses while
few researchers wondered why antigens were much more
 
immunogenic for the specific immune system when applied
with “adjuvants” that stimulated innate immunity (4). DC
“maturation” appears to be the cornerstone between innate
and cognate immunity, but what regulates DC maturation?
DCs are sensors of infection and danger (5) and pathways
leading to DC activation involve at least toll like receptors
and/or proinflammatory cytokine and chemokine recep-
tors (4, 5). However, in non-microbial scenarios such as tu-
morigenesis, transplantation, or atopy, DC activation might
be regulated through other mechanisms whereby a third
party cell could convey stress signals to DCs. The activated
NK cell could be this third party cell, capable of directly
triggering DC maturation (6, 7). In this issue of 
 
The Journal
of Experimental Medicine
 
, three articles shed some light on the
regulatory role of NK cells on the control of DC functions
(6–8).
The relevance of innate effectors such as NK cells in re-
sistance to herpes viridae–related infections (9) and tumors
(10) is being established. NK cell effector functions are reg-
ulated by the balance of activating and inhibitory signals
transmitted by membrane receptors that recognize ligands
on the cell surface of potential target cells (11–13). But
which mechanisms contribute to the “priming” phase of
NK cell activation? While so far, experimental model sys-
tems exploring NK cell recognition patterns used IL-2, a
lymphokine downstream of T cell activation, there is a role
for NK cells early on, before cognate T cell activation for
the control of MCMV viral infections (9, 14, 15). It was
proposed by Fernandez et al. (16) in a mouse model that
DCs could act on the priming arm of innate immunity by
triggering NK cell effector functions in vitro and in vivo in
the setting of a tumor. In line with this observation, bone
marrow–derived DCs were shown to be pivotal for the
control of hepatic mouse NKT cell activation (17). In this
issue of 
 
The Journal of Experimental Medicine
 
, three articles
analyze the regulation of NK cell functions by DCs in hu-
man in vitro model systems (6–8) demonstrating that DCs
can act on the priming phase of NK cell activation.
This commentary tries to highlight a few important links
between the two players of innate immunity, DCs and NK
cells, which may impinge on the course of immune disor-
ders or translate into novel avenues for therapy.
 
DCs and NK Cell Trafficking in Resting and Inflammatory
Conditions.
 
The current concept of the multistep process
of leukocyte recruitment into tissues envisions chemotactic
agonists as key effector molecules (18). The rules governing
DC trafficking are being unraveled, but much less informa-
tion is available on the NK cell migratory pathways during
homeostasis or inflammation. Rapid recruitment of DCs is
a hallmark of inflammatory responses at mucosal surfaces
(19) as documented after acute infection with bacteria or
chronic inflammatory diseases (20). The migration and re-
cruitment of NK cells from blood vessels to target tissues
are the first steps in the cascade of events for NK cell acti-
vation. Indeed, after injection of MCMV (15) or MHC
 
class I–negative tumor cells (14), a dramatic recruitment
of activated NK cells at the inflammatory sites has been
reported. Theoretically, both DCs and NK cells may be
attracted to peripheral acute or chronic inflammatory sites
by common sets of chemokines and could induce in auto-
crine loops their reciprocal migration (21, 22). It is also
conceivable that both DCs and NK cells could be directly
recruited into lymph nodes from blood through high en-
dothelial venules during inflammation, as recently demon-
strated for monocytes, where a predominant role for
monokines secreted in situ or in the periphery was high-
lighted (23). In contrast to the CD16
 
 
 
 NK cell subset,
CD16
 
 
 
 NK cells respond most dramatically to the CC
chemokine receptor 7 (CCR7) ligands (Epstein-Barr virus–
induced molecule 1 ligand chemokine [ELC], secondary
lymphoid tissue chemoattractant [SLC]) and CXC che-
mokine receptor 3 (CXCR3) ligands (IP-10 and ITAC)
and express high levels of L selectin (24) potentially en-
abling them to reach lymph nodes. Nothing is known
about a potential interaction between DC and NK cells in
homeostatic resting conditions. The CD16
 
 
 
CD56
 
 
 
 frac-
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tion of human resting peripheral blood NK cells express
CXCR1 and CX3CR1, and respond to IL-8 and fractal-
kine, chemokines constitutively expressed in epithelia
where immature DC accumulate (24).
However, comprehensive immunohistochemistry studies
using novel and specific DC and NK cell surface markers
are needed to validate the relevance of a DC/NK cell in-
teraction in the course of homeostasis, acute and chronic
inflammation.
 
DCs as Surrogates for “NK Cell Stimulatory Factors”.
 
The notion currently prevailing is that NK cells can be rap-
idly activated in the periphery by chemokines and/or in-
flammatory cytokines in conjunction with NK cell stimula-
tory factors such as IL-12, IFN type 1, or IL-2. However,
NK cell stimulatory factors might not be readily available at
the onset of acute inflammation. Indeed, in the case of IL-
12 produced by DCs (5) or IL-2 secreted by polarized ef-
fector Th1 CD4
 
 
 
 T cells, the adaptive arm of immune
responses is typically required for such cytokines to be re-
leased. In viral infections where type 1 IFNs are produced,
IL-12 secretion by DCs and NK cell responsiveness to IL-
12 are both impaired (25). Moreover, virus-mediated an-
tagonisms to cytokines and chemokines critical for NK cell
activation have been described (26). So, in such circum-
stances of immune subversion, is there a surrogate pathway
for NK cell activation, involving primarily the innate im-
mune system? The pioneering work by Fernandez et al.
(16) reported in a mouse tumor model that after Flt3L in
vivo expansion or adoptive transfer of DCs into B6 mice,
NK cell–dependent antitumor effects were observed, that
were not accounted for by IL-12 nor IFN type 1. A role
for CD8
 
 
 
 
 
 DCs in the Flt3L-mediated NK cell–dependent
antitumor effects was demonstrated, suggesting the capacity
of DCs to activate NK cells. Bone marrow–derived DCs
propagated in GM-CSF and IL-4 were electively capable
of triggering NK cell IFN-
 
 
 
 production and NK cell cyto-
toxicity in 18 h cocultures. A role for IL-4 in complete DC
differentiation was outlined, as GM-CSF propagated DCs
were not able to enhance NK cell lytic activity. In similar
settings, classical NK cell targets (YAC-1 or P815-B7),
when cocultured with NK cells, only trigger IFN-
 
 
 
 pro-
duction. In human in vitro systems, early studies pointed to
a requirement for accessory HLA-DR
 
 
 
 cells in NK cell
killing of virally infected targets (27). Other groups made
similar observations in human in vitro systems using
CD34
 
 
 
-derived DCs or monocyte-derived DCs in cocul-
ture with IL-15–differentiated NK cells or IL-2–activated
CD16
 
 
 
/CD56
 
  
 
NK cells (28, 29). In this issue, Piccioli et
al. (6), Gerosa et al. (7), and Ferlazzo et al. (8) shed some
light on the regulation of human resting NK cell activation
by DCs.
Gerosa et al. (7) show that the cross-talk between imma-
ture DCs and resting NK cells leads to cell activation only
in the presence of microbial stimuli. They demonstrate that
resting fresh NK cells are activated by autologous or alloge-
neic DCs in the presence of concomitant inflammatory
stimuli (LPS, IFN-
 
 
 
, mycobacterium tuberculosis). Upreg-
ulation of CD69, and enhancement of cytotoxicity against
Daudi, are hallmarks of CD3
 
 
 
CD16
 
 
 
CD56
 
 
 
 NK cell re-
activity after coculture with DCs in the presence of LPS.
CD3
 
 
 
 T cells do not respond to DCs subjected to LPS
within 24 h. DC-mediated NK cell activation in the pres-
ence of LPS involves a cell to cell contact and neutralizing
Ab anti–IL-2 or anti–IL-12 do not inhibit these effects. It is
noteworthy that DC stimulation with LPS and not IFN-
 
 
 
allows NK cell IFN-
 
 
 
 production, an effect associated with
IL-12 production.
In the absence of microbial agents, Piccioli et al. (6)
show that only when DC numbers predominate, i.e., con-
ditions of a low NK:DC ratio, the DC/NK cell interaction
results in NK cell activation (CD69 upregulation at 48 h
DC/NK coculture).
Ferlazzo et al. (8) demonstrate that mature DC activated
with a cocktail of inflammatory cytokines can promote hu-
man resting NK cell effector functions. However, in con-
trast to the other authors, they also show that immature
DCs are capable of triggering resting NK cell functions at a
low DC:NK ratio (1:10). This apparently conflicting result
might be explained by the prolonged coculture periods
used by the authors (7 d versus 24–48 h for the two other
teams) and/or DC culture regimen (usage of 1% donor
plasma for DC differentiation).
In as much as immature DC do not express MICA or
ULBP-2 molecules, and as anti-NKp30 mAb do not pre-
vent DC-mediated NK cell activation, a role for such
NKG2D and NKp30 ligands seems unlikely (discussed in
reference 8).
Altogether, these data stress that innate players, i.e.,
DCs can direct expansion (8) and effector functions (7, 8)
of NK cells in the absence of exogenous adaptive-type
(IL-2) cytokines.
 
NK Cells Are Sensors of Danger for DCs.
 
Specialized an-
tigen presenting cells such as DCs are sensors of “microbes”
(5). Their activation leads to consequent increase in immu-
nogenicity with delivery of signal 1 (peptide loading on
MHC class I and II), of signal 2 (increased levels of costim-
ulatory molecules), and signal 3 (polarizing cytokines).
How do “bugs” trigger DC activation? (a) Direct activa-
tion of DCs via Toll-like receptors has been shown. Several
toll-like receptors have been described on DCs, likely co-
operating to widen the repertoire of recognition specificity,
and triggering DC maturation in a nuclear factor (NF)-
 
 
 
B–
dependent manner (4, 5). Heat shock proteins released by
necrotic cells may also mature DCs and be considered as
danger signals. (b) Indirect activation of DCs by signs of in-
flammation, i.e., proinflammatory cytokines (IL-1, IL-18,
TNF-
 
 
 
) and chemokines, is also NF-
 
 
 
B dependent. (c)
In contrast to LPS-triggering, TREM-2/DAP12–induced
DC maturation (30), like that initiated by the FcRs (31), is
dependent on protein tyrosine kinase (PTKs) and extracel-
lular signal–regulated kinase (ERK) signaling. TREM2/
DAP12 engagement in DCs leads to upregulation of
CCR7, CD40, CD86, and DC survival but not IL-12 nor
TNF-
 
 
 
 production. So far, TREM2/DAP-12 ligands re-
main unknown (30). (d) In situations where pathogens lack
PAMPs, or during transplantation or tumor growth, is 
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there a role for a third party cell to convey “stress or bug”
signals to DCs? NK cells can be turned on by IFN type I
(viruses [9, 25]) or by inducible ligands for NK cell activat-
ing receptors, i.e., CD94/ NKG2D (tumors [10]) and
could represent a first line of danger mediation.
In this issue, two articles demonstrate that activated NK
cells promote DC maturation. In the absence of microbial
stimulus, IL-2–activated NK cells can trigger activation
of immature DC (upregulation of CD80, CD86, CD83,
HLA-DR, CCR7) resulting in enhancement of DC allo-
stimulatory capacity (6, 7). IL-2–activated NK cells dramat-
ically boost IL-12 and TNF-
 
 
 
 production by DCs in the
presence of inflammatory stimuli. IL-2–activated NK cells
induced DC maturation at a similar extent as LPS. It is of
interest that IFN-
 
 
 
 alone was almost inefficient at inducing
DC maturation in the absence of NK cells, suggesting an
IFN-
 
 
 
–mediated-positive feed back loop that augments
both NK cell and DC activation. Activated NK cell–medi-
ated DC triggering involves a cell to cell contact and partly
soluble mediators such as IFN-
 
 
 
 plus TNF-
 
 
 
, TNF-
 
 
 
playing a predominant role. Although activated T cells also
induce DC maturation, NK cells are the only resting cell
type within peripheral blood that can be readily and rapidly
activated by IL-2 to mediate this function. TNF-
 
 
 
 pro-
duced by DCs and IFN-
 
 
 
 produced by IL-2–activated NK
cells variably contribute to enhance induction of DC matu-
ration. High concentrations of both TNF-
 
  
 
plus IFN-
 
 
 
synergized to induce DC maturation but never to the ex-
tent induced by IL-2–activated NK cells or LPS.
Gerosa et al. (7) also demonstrate rapid DC maturation
triggered by NK cells activated by DCs. Indeed, after rest-
ing DC/NK encountering in the presence of IFN-
 
 
 
 or
other microbial agents such as LPS or mycobacterium tu-
berculosis, DCs upregulate CD86 and produce TNF-
 
 
 
 and
IL-12p40. In addition, Piccioli et al. (6) point to a critical
role of the DC/NK cell ratio for optimal NK cell–medi-
ated DC activation. Dealing with IL-2–activated NK cells,
they demonstrate that, at low NK/immature DC ratios (1/5
and up to 1/40), the DC/NK cell interaction dramatically
enhances (a) DC cytokine production (IL-12, TNF-
 
 
 
) in a
cell to cell contact–dependent manner, (b) DC maturation
which was dependent on endogenously produced TNF-
 
 
 
(autocrine loop, membrane bound TNF-
 
 
 
) and not on IL-
12, IFN-
 
 
 
, IFN type 1, Fas, ICAM3, CD40L, CD80,
CD86, and LFA1 (not shown). In contrast, in the absence
of stress (IL-2, microbial agents), DC activation after NK
cell interaction might be ongoing during overwhelming
NK cell responses. Indeed, only a high NK/DC ratio leads
to DC activation in resting culture conditions.
These data point to a critical role for NK cell activation
in triggering DC maturation, therefore linking innate and
cognate immunity.
 
Turning Off Acute Immune Responses: NK Cells as a Con-
trol/Switch for DC Activation.
 
NK cells arrive at sites of
infection within minutes to hours after pathogen invasion
(9, 14, 15). Here they should encounter resident DCs al-
ready responding to signals derived from invading patho-
gens and proinflammatory cytokines. Given the ability of
activated DCs and NK cells to influence and recruit each
other, a rapid influx of both DCs and NK cells will ensue.
In this issue, Piccioli et al. (6) and Ferlazzo et al. (8) shed
some light on the role of NK cells to shut off DC-medi-
ated immune responses.
Piccioli et al. (6) show that the outcome between DC
activation or death depends on the DC/NK cell ratio. At
high NK:DC ratios (5/1), inhibition of DC functions is the
dominant feature of the DC interaction with activated NK
cells due to direct NK cell killing of immature DC. Indeed,
both DC maturation and DC cytokine production (TNF-
 
 
 
,
IL-12), observed at low activated NK/immature DC ratios
(1/5 and up to 1/40), are abrogated at high NK:DC ratios.
Ferlazzo et al. (8) demonstrates (versus mature DCs) elec-
tive killing of immature DCs by activated NK cells. NK
cells, after activation by IL-2 or DCs, exhibit potent killing
activity against immature DCs and secrete IFN-
 
 
 
. Acti-
vated NK cell lysis of immature DCs is blocked electively
by anti-NKp30 Ab (and not by anti-NKp44, NKp46,
NKG2D, 2B4, NKp80). In contrast, mature DCs are resis-
tant to NK cell lysis. NK cells become capable of recogniz-
ing mature DCs in a NKp30-dependent fashion only in the
presence of anti-MHC class I Ab.
These data highlight a regulatory loop whereby DC-
mediated NK cell activation leads to DC killing in case of
overwhelming NK cell responses.
 
Putative Scenarios in the DC/NK Cell Bidirectional Cross-
talk.
 
In this issue, a bidirectional cross-talk between DCs
and NK cells is described whereby DC-mediated NK cell
activation and NK cell killing of DCs is the control/switch
for DC activation or inhibition. This provides links be-
tween innate and cognate immune responses (Fig. 1).
After encounter with a pathogen or a danger, immature
DCs mature and induce resting NK cell activation. NK
cells are innate cytotoxic effectors but also regulatory cells
releasing cytokines involved in innate resistance and adap-
tive immunity. They are required in resistance to Leishma-
niasis for IL-12–mediated Th1 responses, in resistance to
herpes viruses via IFN-
 
 
 
 and/or cytotoxicity, in resistance
to tumors expressing ligands for activating receptors, and in
the regulation of B cell responses and autoimmunity (32).
Early at the onset of infection, before antigen-specific
cognate T cells are expanded, NK cells become activated
and amplify the maturation of DCs induced by microbial
products or by virus-induced IFNs. Activated NK cells, by
lysing target cells or surrounding immature DCs that have
phagocytosed and processed foreign antigen, provide anti-
genic cellular debris internalized by maturing DCs that
could be presented to T cells in lymph nodes. Thus, NK
cells likely participate in DC-mediated cognate T cell re-
sponses. At later stages of immune responses, activated NK
cells overwhelm surrounding DCs, the cross-talk between
activated NK and DCs leads to NK cell–mediated DC
death shutting off the antigen presentation.
The interaction between immature DCs and activated
NK cells results in either DC maturation or cell death. The
mechanisms that determine the outcome between death
and maturation depend on a dynamics between DC and 
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NK cell density and on the DC maturation stage. In addi-
tion, the cytokine pattern of DC activation after interaction
with NK cells in response to various microbial stimuli
could influence polarization of T cell responses. There
might be physiopathological conditions whereby a disequi-
librium of ratio between NK cells and DCs might result in
aberrant cell activation (large granular lymphocytic leuke-
mias associated with autoimmune disorders, Flt3L-medi-
ated DC expansion).
The molecular basis of the DC-mediated NK cell activa-
tion remain unknown. A notion that emerges from these
papers is that NK cells might need a “priming phase” of ac-
tivation relying on recognition of DC ligands. This “prim-
ing phase” should be distinguished from the “effector
phase” of NK cell activation, as receptors mediating DC or
target recognition by NK cells (i.e., NKp30 NCR,
CD40L, CD28) do not seem to be involved in the DC-
mediated NK cell priming. DC/NK cell interaction might
lead to upregulation of inducible NCR on NK cells (such
as NKp44) or downmodulation of NK cell killer inhibitory
receptor expression and/or engagement of critical costimu-
latory molecules (ICAMs, CD48, CD58). Indeed, NK cell
function is mediated by the opposing effects of two sets of
NK receptors defined operationally as activating or inhibi-
tory receptors (11–13). Augmentation of antitumor effects
by specific NK cell inhibitory receptor blockade was dem-
onstrated in vitro and in vivo (33). Based on the laws of
NK cell alloreactivity, i.e., KIR epitope mismatching for
HLA, Velardi’s group reported that killing of KIR epitope
mismatched myeloid leukemias can be predicted by the ly-
sis of corresponding normal blood cells and by specific
HLA disparities (34). Delivery of positive signals through
NK cell receptors does contribute to antitumor defense.
Ectopic expression of ligands for NK cell activating recep-
tors on tumor cells allowed NK cell–mediated tumor rejec-
tion in various mouse tumor models in vivo (8).
 
 
 
Delivery
of positive signals through NK cell receptors (Ly49H) was
also relevant in anti-MCMV viral defense (15, 35). The
study of the DC/NK cell immune synapse might shed
some light on the supramolecular organization and poten-
tial intercellular transfer of MHC class I and/or ligands for
NCR to the NK cell (36). Moreover, understanding
the involvement of the non-redundant ITAM bearing
polypeptides, i.e., CD3
 
 
 
, FcR
 
 
 
, and KARAP-DAP12 in
the DC-mediated NK cell activation might be instrumental
for the characterization of the DC ligands (37).
Based on this novel DC/NK cell interaction, alternative
NK cell–based immunotherapy strategies could be designed
(unpublished data) that could substitute for the toxic sys-
temic administration of NK cell stimulatory cytokines.
Figure 1. Bidirectional cross-talk between DCs and NK cells. After encounter with a pathogen, immature DCs (iDC) secrete TNF  with or without
IL-12, undergo maturation, and induce resting NK cell activation. The interaction between iDCs and activated NK cells results in either DC maturation
or cell death. The mechanisms that determine the outcome between death and maturation depend on a dynamics between DCs and NK cell density and
on the DC maturation stage. At high iDC/NK cell ratio, DCs become activated and resistant to NK cell lysis, enabling amplification of NK cell activa-
tion and elicitation of cognate immune responses. When NK cells are overwhelming, iDC-mediated NK cell lysis turns off local immune responses. 
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